{
  "abstract": "Objective: SURMOUNT‐REAL UK will evaluate the effectiveness of tirzepatide when offered in addition to standard‐of‐care (SoC) in adults with Class I obesity (BMI ≥ 30 and ≤ 34.9 kg/m2) and without diabetes in a UK primary care setting.\n\nMethods: A 5‐year, phase 4, multicenter, open‐label, pragmatic randomized clinical trial is enabled through access to participants' integrated electronic healthcare record data. The study will enroll approximately 3000 participants from Greater Manchester, UK, who are randomly assigned in a 1:1 ratio to receive either tirzepatide and SoC or SoC alone.\n\nResults: The primary endpoint is the percent change in body weight from baseline to Month 24, with the time to onset of type 2 diabetes to Month 60 being the key secondary endpoint. Additional endpoints include the impact of tirzepatide versus SoC on obesity‐related complications, health‐related quality of life, healthcare resource utilization, productivity, employment, and sickness‐related absences.\n\nConclusions: SURMOUNT‐REAL UK employs a novel study design to evaluate real‐world health outcomes and potential long‐term benefits for both participants and the healthcare system associated with the delivery of pharmacological obesity treatment at a population level. The study is intended to generate critical evidence to support informed decision‐making in obesity management, clinical guideline development, and healthcare policy.\n\nTrial Registration: ClinicalTrials.gov identifier: NCT07247084",
  "abstract_shown": true,
  "affiliations": [
    "Division of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine and Health University of Manchester Manchester UK",
    "Diabetes, Endocrinology and Metabolism Centre Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre Manchester UK",
    "Eli Lilly and Company Basingstoke UK",
    "NorthWest EHealth (NWEH) Ltd. Manchester UK",
    "Eli Lilly and Company Indianapolis Indiana USA",
    "Department of Cardiovascular and Metabolic Medicine University of Liverpool Liverpool UK",
    "School of Cardiovascular and Metabolic Health University of Glasgow Glasgow UK",
    "Diabetes Research Centre University of Leicester Leicester UK",
    "NIHR Leicester Biomedical Research Centre Leicester UK",
    "Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health University of Oxford Oxford UK"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 15,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Martin K. Rutter"
    },
    {
      "affs": [
        2
      ],
      "name": "Julie Mount"
    },
    {
      "affs": [
        0,
        3
      ],
      "name": "J. Martin Gibson"
    },
    {
      "affs": [
        2
      ],
      "name": "Joanne Webb"
    },
    {
      "affs": [
        4
      ],
      "name": "Cheryl Marler"
    },
    {
      "affs": [
        2
      ],
      "name": "Catherine Reed"
    },
    {
      "affs": [
        4
      ],
      "name": "Mugdha Gore"
    },
    {
      "affs": [
        4
      ],
      "name": "Wenyu Ye"
    },
    {
      "affs": [
        4
      ],
      "name": "Elisa Gomez Valderas"
    },
    {
      "affs": [
        5
      ],
      "name": "John Wilding"
    },
    {
      "affs": [
        6
      ],
      "name": "Naveed Sattar",
      "orcid": "0000-0002-1604-2593"
    },
    {
      "affs": [
        7,
        8
      ],
      "name": "Melanie J. Davies"
    },
    {
      "affs": [
        7
      ],
      "name": "Kamlesh Khunti"
    },
    {
      "affs": [
        9
      ],
      "name": "Richard Haynes"
    },
    {
      "affs": [
        2
      ],
      "name": "Rachel L. Batterham"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/axe8c6xssr13z.bib",
  "cited_by": 0,
  "doi": "10.1002/oby.70247",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13716189/",
  "id": "axe8c6xssr13z",
  "issns": [
    "1930-7381",
    "1930-739X"
  ],
  "landing_url": "https://doi.org/10.1002/oby.70247",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Clinical Trials and Investigations"
    ],
    [
      "heading",
      "ORIGINAL ARTICLE"
    ],
    [
      "heading",
      "Original Article"
    ],
    [
      "openalex",
      "2736|Pharmacology and Obesity Treatment"
    ]
  ],
  "openalex": "W7164845369",
  "pdf_url": null,
  "pmcid": "PMC13716189",
  "pmid": "42297568",
  "published": "2026-06-15",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/axe8c6xssr13z.ris",
  "sources": [
    {
      "first_seen": "2026-11-01T12:23:14Z",
      "native_id": "PMC13716189",
      "source": "pmc",
      "url": "https://doi.org/10.1002/oby.70247"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2736|Pharmacology and Obesity Treatment",
      "subfield": "pharmacology-toxicology"
    }
  ],
  "title": "SURMOUNT‐REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity",
  "title_text": "SURMOUNT‐REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity",
  "type": "peer-reviewed",
  "updated_at": "2026-11-01T12:23:14Z",
  "url": "https://research.draconitic.com/paper/axe8c6xssr13z",
  "venue": "Obesity (Silver Spring, Md.)",
  "versions": []
}